I was a partner in a SMID cap investment firm and a member of TIAA’s six-time Lipper Award winning investment team for almost eight years. During that time, I ran a circa $1B biotechnology investment portfolio and got strong work reviews for my performance. I have followed hundreds of biotech companies over almost two decades, and developed clear ideas about the characteristics of drug development projects and management teams that lead to success. While I can handle virtually any aspect of public or private investment due diligence, I am happy to do a complete evaluation of a family of related biotech companies and recommend a comprehensive investment strategy.